肿瘤内皮细胞与淋巴细胞密度在接受免疫治疗的晚期肝细胞癌患者中的不同意义

英文原题：Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy.

查看英文原题

Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapy.

PubMed 2025/12/11（内容时间） NPJ Precis Oncol Q1 · IF 9.9（JCR 2025）

肝细胞癌地区：韩国

登录后收藏与关注全文解读加入对比

研究概要

对163例患者治疗前H&E图像中的免疫/非免疫细胞空间分布，采用AI/深度学习模型进行了回顾性分析。

中文摘要

我们研究了基于人工智能（AI）的肿瘤微环境分析是否与接受免疫检查点抑制剂（ICI）治疗的不可切除肝细胞癌（HCC）患者的治疗疗效相关。使用AI/深度学习模型，对163例患者治疗前H&E图像中的免疫/非免疫细胞空间分布进行了回顾性分析。高肿瘤内皮细胞（TEC）密度与阿替利珠单抗联合贝伐珠单抗（atezo-bev）队列中显著更长的无进展生存期（PFS）相关（HR 0.51 [0.27-0.97]；p = 0.037），但在抗PD-1单药治疗队列中不相关（HR 1.02 [0.59-1.77]；p = 0.935）。相反，以高瘤内TIL密度为特征的炎症免疫表型，可预测抗PD-1单药治疗后更长的PFS（HR 0.50 [0.25-0.99]；p = 0.042），但不能预测atezo-bev治疗后的PFS（HR 0.92 [0.50-1.69]；p = 0.762）。我们使用AI/深度学习模型进行的探索性分析表明，高TEC密度可预测atezo-bev治疗更优的结局，而TIL存在与HCC患者抗PD-1单药治疗疗效改善相关，提示其在治疗选择方面具有潜在的临床应用价值。

展开英文摘要原文

We investigated whether artificial intelligence (AI)-based tumor microenvironment profiling correlates with treatment efficacy in unresectable hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitor (ICI) therapies. Spatial distribution of immune/non-immune cells from pretreatment H&E images of 163 patients was retrospectively analyzed using an AI/deep-learning model. High tumor endothelial cell (TEC) density was associated with significantly longer progression-free survival (PFS) in the atezolizumab plus bevacizumab (atezo-bev) cohort (HR 0.51 [0.27-0.97]; p = 0.037) but not in the anti-PD-1 monotherapy cohort (HR 1.02 [0.59-1.77]; p = 0.935). Conversely, inflamed immune phenotype, characterized by high intratumoral TIL densities, predicted longer PFS after anti-PD-1 monotherapy (HR 0.50 [0.25-0.99]; p = 0.042) but not after atezo-bev (HR 0.92 [0.50-1.69]; p = 0.762). Our exploratory analysis using AI/deep-learning model demonstrated high TEC density predicted superior outcomes with atezo-bev, while TIL presence correlated with improved anti-PD-1 monotherapy efficacy in HCC patients, suggesting potential clinical applicability in treatment selection.

论文信息

作者: Kim G、Kang B、Hong JY、Kang H、Kim JS、Hwang S、Lee SH、Jung SH
第一作者单位: Department of Pathology, CHA Bundang Medical Center, Seongnam, Korea.South Korea
通讯作者单位: Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. minidoctor@cha.ac.kr.South Korea
期刊: NPJ precision oncology2025 Dec 11

原文标识: PubMed 41381712　·　DOI 10.1038/s41698-025-01207-x

在 PubMed 查看 → 出版商原文（DOI）报告译文或资料问题 →